Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)

NCT00440479 is registered in ClinicalTrials.gov with Janssen-Cilag B.V. as lead sponsor.

NCT NCT00440479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00440479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)
Lead sponsor
Janssen-Cilag B.V.
Phase
Observational
Overall status
Completed
Start date
September 30, 2006
Completion date
January 31, 2011
Enrollment
11 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hematological neoplasms, multiple myeloma